AD, Alzheimers Disease
Conditions
Brief summary
\[F-18\]T807 is being developed as a diagnostic radiopharmaceutical for PET imaging of the human brain.
Detailed description
Siemens Molecular Imaging (SMI) is seeking to determine if \[F-18\]T807 might be useful as a non-invasive assessment tool in the clinical evaluation of subjects with conditions associated with tau protein aggregates, such as Alzheimer's disease. The information collected under this exploratory study will not be used for diagnostic purposes, assessments of the participant's response to therapy or for clinical management of the participants. However, this exploratory study will provide baseline information on the safety, biodistribution, and dosimetry of \[F-18\]T807. These data will aid in the design of future studies of \[F-18\]T807 in patients with Alzheimer's disease. Overall, this study will provide initial data that inform the development of \[F-18\]T807 as the first PET imaging agent for human tau protein related pathology.
Interventions
RADIATION[F18] T807
Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
Sponsors
Avid Radiopharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
; Low Probability for AD Participants (Group 1) * Participant has reached his or her 55th birthday at the time of informed consent (Participant is male or female of any race / ethnicity) * Participant provides written informed consent * Participant is capable of complying with study procedures * Participant is capable of communicating with study personnel * Participant understands and speaks English * Participant has at least an 8th Grade education * In the Investigator's opinion, participant has a low probability of being currently positive for AD as determined by a Mini Mental State Examination (MMSE ≥ 28) defined in APPENDIX VI of protocol T807000, IND 114102 * Participant has no significant hepatic or renal disease as defined by previous medical history and lab results are within the following ranges: * Total bilirubin within 2x institutional upper limits of normal * AST (SGOT) ≤ 2.5 x institutional upper limits of normal * ALT (SGPT) ≤ 2.5 x institutional upper limits of normal * Creatinine ≤ 2x institutional upper limits of normal * BUN within 2x institutional upper limits of normal High Probability for AD Participants (Group 2) * Participant has reached his or her 55th birthday at the time of informed consent (Participant is male or female of any race / ethnicity) * Participant or participant's legally acceptable representative provides written informed consent * Participant is capable of complying with study procedures * Participant is capable of communicating with study personnel * Participant understands and speaks English * Participant has at least an 8th Grade education * In the Investigator's opinion, participant has a high probability of being currently positive for AD that is determined by a Mini Mental State Examination (MMSE \< 17) defined in APPENDIX VI of protocol T807000, IND 114102. * Participant has no significant hepatic or renal disease as defined by previous medical history, and lab results are within the following ranges: * Total bilirubin within 2x institutional upper limits of normal * AST (SGOT) ≤ 2.5 x institutional upper limits of normal * ALT (SGPT) ≤ 2.5 x institutional upper limits of normal * Creatinine ≤ 2x institutional upper limits of normal * BUN within 2x institutional upper limits of normal
Exclusion criteria
; All Participants * Female participant is pregnant or nursing * Participant has prior history of stroke or other condition of the head or neck that, in the Investigator's opinion, might affect circulation to the head or image interpretation * Participant has other neurodegenerative disease that is associated with cognitive impairment or dementia * Participant has a medical condition that might be associated with elevated amyloid levels, such as amyloid angiopathy, familial amyloidosis, chronic kidney dialysis, Down's syndrome * Participant has a history of significant cerebrovascular disease * Participant has previously received \[F-18\]T807 at any time * Participant has been involved in an investigative, radioactive research procedure within the past 14 days * Participant has any other condition or personal circumstance that, in the judgment of the Investigator, might interfere with the collection of complete data or data quality * Participant has a history in the last five years of significant prescription or non-prescription drug or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the bio-distribution and radiation dosimetry of [F-18]T807 in participants with low probability of Alzheimer's disease (AD) using PET/CT whole body imaging | up to 15 days per patient | — |
| To evaluate the metabolism of [F-18]T807 in participants with low probability of AD using serial blood samples collected pre- and post-IP administration | up to 15 days per patient | — |
| To evaluate [F-18]T807 uptake and signal/background information in brain PET/CT imaging of participants with a high probability of currently being positive for AD and age-matched participants with a low probability of currently being positive for AD | upto 15 days per patient | — |
| To assess the safety of IV administration of [F-18]T807 | up to 24 hours post [F18]T807 administration | Safety will be monitored for all subjects by the: * Number of subjects experiencing adverse events from baseline to 24 hours post-administration. * Number and type of adverse events. * Changes in clinical laboratory assessments (CBC and clinical chemistry)from baseline to 24 hours post administration. * Changes in physical examination from baseline to 24 hours post administration. * Changes in vital sign measurements (systolic blood pressure \[mmHg\]; diastolic blood pressure \[mmHg\], pulse rate \[bpm\] and body temperature) from baseline prior to \[F-18\]T807 administration, at 60 +/- 15 minutes post administration, at the end of the final imaging session (approximately 100 minutes post administration)and at 24 hours post administration. * Changes in ECG measurements, from baseline prior to \[F-18\]T807 administration, at 60 +/- 15 minutes post administration, at the end of the final imaging session (approximately 100 minutes post administration) and at 24 hours post administration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To begin collection of baseline [F-18]T807 PET/CT imaging data | up to 15 days per patient | The secondary endpoint of this investigational study is the collection of baseline whole body PET/CT images and PET/CT images of the brain, following administration of \[F-18\]T807 |
| To gain information to improve the study design for the conduct of future trials | up to 15 days per patient | The secondary endpoint of this investigational study is the collection of baseline whole body PET/CT images and PET/CT images of the brain, following administration of \[F-18\]T807 |
Countries
United States
Outcome results
None listed